Dummer, Reinhard <br/><br/>
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.  [electronic resource] 

 -  The Lancet. Oncology  10 2018 
 - 1315-1327 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(18)30497-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Benzimidazoles--administration & dosage<br/>Biomarkers, Tumor--genetics<br/>Carbamates--administration & dosage<br/>Disease Progression<br/>Female<br/>Genetic Predisposition to Disease<br/>Humans<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Mutation<br/>Phenotype<br/>Progression-Free Survival<br/>Protein Kinase Inhibitors--administration & dosage<br/>Proto-Oncogene Proteins B-raf--genetics<br/>Skin Neoplasms--drug therapy<br/>Sulfonamides--administration & dosage<br/>Time Factors<br/>Vemurafenib--administration & dosage<br/>Young Adult